Rosiglitazone protects against beta cell destruction in ZDF (Type 2) diabetic rats

The progression of type 2 diabetes involves insulin resistance, impairment in insulin secretion, and eventual loss of β‐cell mass. Current therapies largely address insulin sensitivity and secretion but it is also important that therapies be found which protect against β‐cell loss. Finegood et al (2000) have reported that rosiglitazone (RSG) treatment largely prevents loss of β‐cell mass. We have confirmed this observation and present new …